|  |
| --- |
|  |
| **Characteristic** | | **ASA Users**  **(N = 1363)** | **ASA Non-users**  **(N = 1681)** | **P-value** |
| Age, mean (SD) | | 68 (8) | 64 (9) | <0.0001 |
| Female gender, n (%) | | 604 (44.3) | 1033 (61.5) | <0.0001 |
| Race, n (%) | |  |  | 0.0688 |
| White | | 1252 (93.7) | 1517 (92.5) |  |
| Black | | 59 ( 4.4) | 70 ( 4.3) |  |
| Other | | 25 ( 1.9) | 53 ( 3.2) |  |
| Hispanic ethnicity, n (%) | | 34 ( 2.8) | 58 (3.9) | 0.1416 |
| BMI (kg/m2), mean (SD) | | 28.8 (5.4) | 28.0 (5.5) | <0.0001 |
| eGFR (mL/min/1.73 m2), mean (SD) | | 76.0 (16.8) | 80.8 (15.8) | <0.0001 |
| Cigarette use, n (%) | |  |  | 0.2472 |
| Current | | 90 (6.6) | 138 (8.2) |  |
| Former | | 47 (3.5) | 54 (3.2) |  |
| Never | | 1221 (89.9) | 1489 (88.6) |  |
| Pipe Tobacco use, n (%) | |  |  | 0.1654 |
| Current | | 27 (2.0) | 20 (1.2) |  |
| Former | | 6 (0.4) | 5 (0.3) |  |
| Never | | 1324 (97.6) | 1655 (98.5) |  |
| LVEF (%), mean (SD) | | 65.8 (7.4) | 66.5 (6.2) | 0.0103 |
| Atrial fibrillation/flutter rhythm n (%) | | 28 (2.1) | 44 (2.6) | 0.3093 |
| Diabetes N (%) | | 275 (20.3) | 162 (9.7) | <0.0001 |
| Medical history of: | |  |  |  |
| Hypertension, n (%) | | 902 (66.2) | 628 (37.4) | <0.0001 |
| Hyperlipidemia, n (%) | | 822 (60.4) | 463 (27.6) | <0.0001 |
| Diabetes, n (%) | | 196 (14.4) | 106 (6.9) | <0.0001 |
| Heart failure, n (%) | | 39 (2.9) | 29 1.7) | 0.0350 |
| Myocardial infarction, n (%) | | 190 (13.9) | 72 (4.3) | <0.0001 |
| Atrial fibrillation/flutter, n (%) | | 113 (8.3) | 96 (5.7) | 0.0051 |
| Cerebrovascular disease, n (%) | | 90 (6.6) | 84 (5.0) | 0.0577 |
| Peripheral vascular disease, n (%) | | 88 (6.5) | 42 (2.5) | <0.0001 |
| Coronary revascularization, n (%) | | 306 (22.5) | 83 (4.9) | <0.0001 |
| PCI, n (%) | | 203 (14.9) | 65 (3.9) | <0.0001 |
| CABG surgery, n (%) | | 155 (11.4) | 26 (1.6) | <0.0001 |
| Valvular heart surgery, n (%) | | 41 (3.0) | 19 (1.1) | 0.0002 |
| COPD, n (%) | | 104 (7.8) | 114 (6.9) | 0.3617 |
| Cancer, n (%) | | 489 (35.9) | 497 (29.6) | 0.0002 |
| Medications | |  |  |  |
| Aspirin dose >81 mg/d, n (%) | | 353 (25.9) |  |  |
| NSAID, n (%) | | 315 (23.1) | 453 (27.0) | 0.0154 |
| Antihypertensive therapy n (%) | | 51 (3.7) | 35 (2.1) | 0.0060 |
| Beta-blocker, n (%) | | 540 (39.6) | 275 (16.4) | <0.0001 |
| ACEi/ARB, n (%) | | 622 (45.6) | 385 (22.9) | <0.0001 |
| Lipid therapy, n (%) | | 893 (65.5) | 578 (34.4) | <0.0001 |
| Statin, n (%) | | 776 (56.9) | 429 (25.5) | <0.0001 |
| Lipid-Statin, n (%) | | 776 (56.9) | 429 (25.5) | <0.0001 |
| Lipid-Non-Statin, n (%) | | 117 (8.6) | 149 (8.9) | <0.0001 |
| Diuretic, n (%) | | 423 (31.0) | 323 (19.2) | <0.0001 |
| Insulin, n (%) | | 38 (2.8) | 11 (0.7) | <0.0001 |
| Non-insulin diabetic therapy, n (%) | | 179 (13.1) | 103 (6.1) | <0.0001 |
| Oral anticoagulant, n (%) | | 52 (3.8) | 102 (6.1) | 0.0048 |
| 8-isoPGF2α (pg/mg creatinine), mean (SD) | | 1096 (599) | 1149 (663) | 0.0203 |
| Laboratory data | |  |  |  |
| Serum creatinine (mg/dL), mean (SD) | | 0.95 (0.30) | 0.88 (0.27) | <0.0001 |
| Glucose (mg/dL) | | 110 (27) | 104 (21) | <0.0001 |
| Hemoglobin A1C (%), mean (SD) | | 5.8 (0.8) | 5.7 (0.6) | <0.0001 |
| Total cholesterol (mg/dL), mean (SD) | | 175 (36) | 195 (36) | <0.0001 |
| LDL cholesterol (mg/dL), mean (SD) | | 97 (30) | 112 (32) | <0.0001 |
| HDL (mg/dL), mean (SD) | | 55 (17) | 60 (18) | <0.0001 |
| Triglyceride (mg/dL), mean (SD) | | 119 (75) | 116 (68) | 0.2351 |
| Urine albumin Ratio (g/dL), median (IQR) | | 61.2 (34.3,137.8) | 59.2 (34.9,114.8) | 0.2125 |
| CRP (mg/L), mean (SD) | | 3.2 (7.4) | 3.4 (7.3) | 0.4580 |
| Serum insulin (pmol/L), mean (SD) | | 83.2 (65.9) | 70.5 (47.1) | <0.0001 |
| MCP (pg/mL), mean (SD) | | 383 (140) | 380 (136) | 0.5633 |
| IL-6 (pg/mL), mean (SD) | | 2.74 (2.94) | 2.51 (2.93) | 0.0395 |
| Lp-PLA2 (ng/mL), mean (SD) | | 195 (52) | 204 (48) | <0.0001 |
| P-selectin (ng/mL), mean (SD) | | 41.2 (13.8) | 41.3 (13.5) | 0.8124 |
|  | |  |  |  |
|  | |  |  |  |
|  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 2.** Univariate linear regression analyses of the association of variables with urineTXB2-M in aspirin users and non-users. | | | | |
|  | **ASA Users**  (N=1363) | | **ASA Non-users**  (N=1681) | |
| **Variable** | **Standardized Regression Coefficient** | **P-value** | **Standardized Regression Coefficient** | **P-value** |
| Age (years) | 0.084661 | 0.0016 | 0.152928 | <0.0001 |
| Female gender | 0.143685 | <0.0001 | 0.083353 | 0.0006 |
| Race (versus white) |  | 0.1284 |  | 0.0462 |
| Black | 0.051683 | 0.0571 | -0.059802 | 0.0155 |
| Other | -0.017351 | 0.5228 | -0.015688 | 0.5252 |
| Hispanic ethnicity | 0.123911 | <0.0001 | 0.025428 | 0.3244 |
| BMI (kg/m2) | 0.025472 | 0.3449 | 0.045630 | 0.0617 |
| Cigarette use (versus never) |  | <0.0001 |  | <0.0001 |
| Current | 0.142412 | <0.0001 | 0.085403 | 0.0005 |
| Former | 0.030349 | 0.2558 | 0.075534 | 0.0019 |
| Pipe use (versus never) |  | 0.4407 |  | 0.5938 |
| Current | -0.017821 | 0.5088 | -0.019827 | 0.4168 |
| Former | 0.029360 | 0.2759 | -0.015226 | 0.5329 |
| LVEF (%) | -0.029155 | 0.3004 | -0.023034 | 0.3670 |
| Atrial fibrillation/flutter rhythm | 0.054589 | 0.0423 | 0.150148 | <0.0001 |
| Diabetes | 0.111355 | <0.0001 | 0.083815 | 0.0006 |
| Medical history of: |  |  |  |  |
| Hypertension | -0.010847 | 0.6869 | 0.135535 | <0.0001 |
| Hyperlipidemia | -0.064651 | 0.0163 | 0.035628 | 0.1444 |
| Diabetes | 0.087954 | 0.0011 | 0.077875 | 0.0023 |
| Heart failure | 0.027441 | 0.3080 | 0.057835 | 0.0177 |
| Myocardial infarction | 0.003155 | 0.9074 | 0.088702 | 0.0003 |
| Atrial fibrillation/flutter | 0.066042 | 0.0142 | 0.141437 | <0.0001 |
| Cerebrovascular disease | 0.052967 | 0.0488 | 0.096793 | <0.0001 |
| Peripheral vascular disease | 0.047153 | 0.0813 | 0.002112 | 0.9310 |
| Coronary revascularization | 0.004971 | 0.8576 | 0.067661 | 0.0055 |
| PCI | -0.016742 | 0.5414 | 0.058074 | 0.0173 |
| CABG surgery | 0.017313 | 05242 | 0.047353 | 0.0522 |
| Valvular heart surgery | -0.015799 | 0.5569 | 0.039312 | 0.1071 |
| COPD | 0.043989 | 0.1046 | 0.083952 | 0.0006 |
| Cancer | -0.013559 | 0.6143 | 0.041981 | 0.0853 |
| Medications: |  |  |  |  |
| ASA dose | 0.129469 | <0.0001 |  |  |
| NSAID | -0.004733 | 0.8603 | -0.140060 | <0.0001 |
| Antihypertensive use | -0.004105 | 0.8788 | 0.006897 | 0.7775 |
| Beta-blocker | 0.004583 | 0.8657 | 0.118753 | <0.0001 |
| ACEi/ARB | -0.016767 | 0.5339 | 0.047259 | 0.0527 |
| Lipid therapy | -0.062567 | 0.0200 | 0.004903 | 0.8408 |
| Statin | -0.051530 | 0.0556 | 0.039598 | 0.1046 |
| Lipid-Statin | -0.051530 | 0.0556 | 0.039598 | 0.1046 |
| Lipid-No-statin | -0.015134 | 0.5737 | -0.052546 | 0.0312 |
| Diuretic | -0.010140 | 0.7061 | 0.079397 | 0.0011 |
| Insulin | 0.023885 | 0.3744 | 0.003911 | 0.8727 |
| Non-insulin diabetic therapy | 0.080585 | 0.0028 | 0.069487 | 0.0044 |
| Oral anticoagulant | 0.040608 | 0.1315 | 0.188710 | <0.0001 |
| Laboratory: |  |  |  |  |
| 8-isoPGF2α (pg/mg creatinine) | 0.176048 | <0.0001 | 0.190122 | <0.0001 |
| Creatinine (mg/dL) | -0.171747 | <0.0001 | -0.129675 | <0.0001 |
| Glucose (mg/dL) | 0.106507 | <0.0001 | 0.081017 | 0.0009 |
| Hemoglobin A1C (%) | 0.106453 | <0.0001 | 0.118336 | <0.0001 |
| Total cholesterol (mg/dL) | -0.006613 | 0.8072 | -0.072443 | 0.0030 |
| LDL cholesterol (mg/dL) | -0.038648 | 0.1525 | -0.070515 | 0.0039 |
| HDL cholesterol (mg/dL) | -0.012190 | 0.6524 | -0.082174 | 0.0008 |
| Triglycerides (mg/dL) | 0.075001 | 0.0053 | 0.085082 | 0.0005 |
| LN(Urine albumin ratio) (g/dL) | 0.168069 | <0.0001 | 0.134999 | <0.0001 |
| CRP (mg/L) | 0.068296 | 0.0114 | 0.101375 | <0.0001 |
| Serum insulin (pmol/L) | 0.067949 | 0.0119 | 0.114534 | <0.0001 |
| MCP-1 (pg/mL) | 0.048542 | 0.0777 | 0.045726 | 0.0670 |
| IL-6 (pg/mL) | 0.113729 | <0.0001 | 0.159307 | <0.0001 |
| Lp-PLA2 (ng/mL) | 0.010924 | 0.6873 | 0.017394 | 0.4816 |
| P-selectin (pg/mL) | 0.099453 | 0.0002 | 0.098264 | <0.0001 |
| eGFR | 0.122089 | <0.0001 | 0.051936 | 0.0359 |
|  | | | | |